Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Great Tree Pharmacy CoROCO:6469 -0.89%70 Return-on-Tangible-Equity is 16.00% as of Dec. 2025, which is 4% above its 10-year median of 15.45. GuruFocus rates ROCO:6469 with a GF Score™ of 70/100 and a GF Value™ of NT$193.87 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 577 Healthcare Providers & Services companies, Great Tree Pharmacy Co ranks better than 63.6% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Great Tree Pharmacy Co's annualized net income for the quarter that ended in Dec. 2025 was NT$597 Mil. Great Tree Pharmacy Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$3,728 Mil. Therefore, Great Tree Pharmacy Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 16.00%.
The historical rank and industry rank for Great Tree Pharmacy Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:6469'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.46 Med: 15.45 Max: 31.22
Current: 17.01
During the past 13 years, Great Tree Pharmacy Co's highest Return-on-Tangible-Equity was 31.22%. The lowest was 11.46%. And the median was 15.45%.
ROCO:6469's Return-on-Tangible-Equity is ranked better than 63.6% of 577
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs ROCO:6469: 17.01
Great Tree Pharmacy Co (ROCO:6469) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Great Tree Pharmacy Co Return-on-Tangible-Equity Related Terms
Great Tree Pharmacy Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Great Tree Pharmacy Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Great Tree Pharmacy Co Return-on-Tangible-Equity Chart
Great Tree Pharmacy Co Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Great Tree Pharmacy Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Great Tree Pharmacy Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Great Tree Pharmacy Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Great Tree Pharmacy Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.00% mean?
Great Tree Pharmacy Co (ROCO:6469) has a Return-on-Tangible-Equity of 16.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Great Tree Pharmacy Co and its competitors. This is near median its historical median of 15.45. Over the past decade, Great Tree Pharmacy Co's Return-on-Tangible-Equity has ranged from 11.46 to 31.22. According to the industry distribution chart, Great Tree Pharmacy Co ranks #210 out of 577 companies in the Healthcare Providers & Services industry, placing it in the top 36.4%.
Is Great Tree Pharmacy Co's Return-on-Tangible-Equity too high?
Great Tree Pharmacy Co's current Return-on-Tangible-Equity of 16.00% is near median its 10-year median of 15.45. Over the past 10 years, this metric has ranged from a low of 11.46 to a high of 31.22. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.13. Great Tree Pharmacy Co's value of 16.00% is 57.9% above this industry median. Based on the distribution chart, Great Tree Pharmacy Co ranks #210 out of 577 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Great Tree Pharmacy Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Great Tree Pharmacy Co's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Great Tree Pharmacy Co ranks #210 out of 577 companies for Return-on-Tangible-Equity. This puts Great Tree Pharmacy Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.13. Great Tree Pharmacy Co's value of 16.00% is 57.9% above this benchmark. Historically, Great Tree Pharmacy Co's own Return-on-Tangible-Equity has ranged from 11.46 to 31.22 over the past decade. While the company's 10-year median is 15.45 vs. the industry median of 10.13, Great Tree Pharmacy Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 577 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Great Tree Pharmacy Co's current Return-on-Tangible-Equity of 16.00% is 57.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Great Tree Pharmacy Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Great Tree Pharmacy Co's current Return-on-Tangible-Equity is 16.00%, which is near median its own 10-year median of 15.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Tree Pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Great Tree Pharmacy Co (ROCO:6469) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$193.87, compared to a current price of NT$77.80 — trading 59.9% below its estimated fair value. The current Return-on-Tangible-Equity is 16.00%, which is near median its 10-year median of 15.45 and 57.9% above the Healthcare Providers & Services industry median of 10.13. Great Tree Pharmacy Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Great Tree Pharmacy Co (ROCO:6469), the current Return-on-Tangible-Equity is 16.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Great Tree Pharmacy Co (ROCO:6469) Overvalued in 2026?
Based on GuruFocus' analysis, Great Tree Pharmacy Co stock appears to be undervalued.
The current stock price of NT$77.80 is trading 59.9% below its estimated GF Value™ of NT$193.87.
GuruFocus considers Great Tree Pharmacy Co to be Significantly Undervalued.
Key valuation signals for ROCO:6469:
Return-on-Tangible-Equity: 16.00% (near median its 10-year median of 15.45)
GF Value™: NT$193.87 vs. price of NT$77.80 (59.9% below fair value)
Industry Position: 57.9% above the Healthcare Providers & Services median (#210 of 577)
No single metric tells the full story. See the ROCO:6469 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Great Tree Pharmacy Co Ltd engages in management and trading of various drugs, health supplements, maternity and infant products, and cosmetics products. It also provides coordinated medicine procurement services to various clinics, outpatient centers, and medical communities. Besides, it is also an agency for domestic and foreign health care products sold in clinics, outpatient centers, and medical communities. Its products include infant formula, baby diapers, Maternal and Infant Related, Adult drinks, Nutrition and health care, Body care, Daily Necessities, medical equipment, and Pet products.
70GF Score
Get the complete analysis for ROCO:6469
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6469 has been successfully added to your 
